Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
NCT ID: NCT00227461
Last Updated: 2021-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
50 participants
INTERVENTIONAL
2005-09-30
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Seizure Activity in Alzheimer's Disease
NCT01554683
Levetiracetam Treatment of L-dopa Induced Dyskinesias
NCT00076674
Post-stroke Epilepsy: Primary Prophylaxis Study
NCT04858841
Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH
NCT01137110
Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease
NCT04643327
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wait control
Levitiracetam is started after a delay, with dosage and administration as described below.
Levetiracetam first, then wait
subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
Treatment first
Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.
Wait first, then levetiracetam
Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Wait first, then levetiracetam
Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
Levetiracetam first, then wait
subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aphasia
* Can give consent
Exclusion Criteria
* Pregnancy
* Other neurological condition
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Kessler Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
A. M. Barrett, MD
Director, Stroke Rehabilitation Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
A.M. Barrett, MD
Role: PRINCIPAL_INVESTIGATOR
Kessler Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kessler Foundation
West Orange, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
none applicable
Identifier Type: -
Identifier Source: secondary_id
AMBarrett1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.